[15] X. Chen, C. Su, S. Ren, C. Zhou, T. Jiang, Pan-cancer analysis of KEAP1 mutations
as biomarkers for immunotherapy outcomes, Ann. Transl. Med. 8 (4) (2020) 141.
[16] X. Xu, Y. Yang, X. Liu, N. Cao, P. Zhang, S. Zhao, D. Chen, L. Li, Y. He, X. Dong,
K. Wang, H. Lin, N. Mao, L. Liu, NFE2L2/KEAP1 mutations correlate with higher
tumor mutational burden value/PD-L1 expression and potentiate improved clinical
outcome with immunotherapy, Oncologist 25 (6) (2020) e955–e963.
[17] V.C. Cordeiro de Lima, M. Corassa, E. Saldanha, H. Freitas, O. Arrieta, L. Raez,
S. Samtani, M. Ramos, C. Rojas, M. Burotto, D.F. Chamorro, G. Recondo, A. RuizPatino, L. Mas, L. Zatarain-Barron, S. Mejia, J. Nicolas Minata, C. Martin,
J. Bautista Blaquier, R. Motta Guerrero, C. Aliaga-Macha, C. Carracedo,
C. Ordonez-Reyes, J.E. Garcia-Robledo, L. Corrales, C. Sotelo, L. Ricaurte,
N. Santoyo, M. Cuello, E. Jaller, J. Rodriguez, P. Archila, M. Bermudez, T. Gamez,
A. Russo, L. Viola, U. Malapelle, D. de Miguel Perez, C. Rolfo, R. Rosell, A.
F. Cardona, STK11 and KEAP1 mutations in non-small cell lung cancer patients:
descriptive analysis and prognostic value among Hispanics (STRIKE registryCLICaP), Lung Cancer 170 (2022) 114–121.
[18] S. Koyama, E.A. Akbay, Y.Y. Li, A.R. Aref, F. Skoulidis, G.S. Herter-Sprie, K.
A. Buczkowski, Y. Liu, M.M. Awad, W.L. Denning, L. Diao, J. Wang, E.R. ParraCuentas, M. Wistuba II, T. Soucheray, H. Thai, S. Asahina, A. Kitajima, J.D. Altabef,
K. Cavanaugh, P. Rhee, H. Gao, P.E. Zhang, T. Fecci, M.D. Shimamura, J.
V. Hellmann, F.S. Heymach, G.J. Hodi, D.A. Freeman, G. Barbie, P.S. Dranoff, K.K.
W. Hammerman, STK11/LKB1 deficiency promotes neutrophil recruitment and
proinflammatory cytokine production to suppress T-cell activity in the lung tumor
microenvironment, Cancer Res. 76 (5) (2016) 999–1008.
[19] F. Skoulidis, M.E. Goldberg, D.M. Greenawalt, M.D. Hellmann, M.M. Awad, J.
F. Gainor, A.B. Schrock, R.J. Hartmaier, S.E. Trabucco, L. Gay, S.M. Ali, J.A. Elvin,
G. Singal, J.S. Ross, D. Fabrizio, P.M. Szabo, H. Chang, A. Sasson, S. Srinivasan,
S. Kirov, J. Szustakowski, P. Vitazka, R. Edwards, J.A. Bufill, N. Sharma, S.I. Ou,
N. Peled, D.R. Spigel, H. Rizvi, E.J. Aguilar, B.W. Carter, J. Erasmus, D.
F. Halpenny, A.J. Plodkowski, N.M. Long, M. Nishino, W.L. Denning, A. GalanCobo, H. Hamdi, T. Hirz, P. Tong, J. Wang, J. Rodriguez-Canales, P.A. Villalobos,
E.R. Parra, N. Kalhor, L.M. Sholl, J.L. Sauter, A.A. Jungbluth, M. Mino-Kenudson,
R. Azimi, Y.Y. Elamin, J. Zhang, G.C. Leonardi, F. Jiang, K.K. Wong, J.J. Lee, V.
A. Papadimitrakopoulou, V.A. Wistuba II, G.M. Miller, J.D. Frampton, A.
T. Wolchok, P.A. Shaw, P.J. Janne, C.M. Stephens, W.J. Rudin, L.A. Geese, J.V.
H. Albacker, STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant
lung adenocarcinoma, Cancer Discov. 8 (7) (2018) 822–835.
[20] G.J. Riely, M.G. Kris, D. Rosenbaum, J. Marks, A. Li, D.A. Chitale, K. Nafa, E.
R. Riedel, M. Hsu, W. Pao, V.A. Miller, M. Ladanyi, Frequency and distinctive
spectrum of KRAS mutations in never smokers with lung adenocarcinoma, Clin.
Cancer Res. 14 (18) (2008) 5731–5734.
[21] T.L. Ng, Y. Liu, A. Dimou, T. Patil, D.L. Aisner, Z. Dong, T. Jiang, C. Su, C. Wu,
S. Ren, C. Zhou, D.R. Camidge, Predictive value of oncogenic driver subtype,
programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of
PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung
cancer, Cancer 125 (7) (2019) 1038–1049.
[22] M. Sebastian, KRAS G12C-mutated advanced non-small cell lung cancer: a realworld cohort from the German prospective, observational, nation-wide CRISP
Registry (AIO-TRK-0315), Lung Cancer 154 (2021) 51–61.
[23] J. Canon, K. Rex, A.Y. Saiki, C. Mohr, K. Cooke, D. Bagal, K. Gaida, T. Holt, C.
G. Knutson, N. Koppada, B.A. Lanman, J. Werner, A.S. Rapaport, T. San Miguel,
R. Ortiz, T. Osgood, J.R. Sun, X. Zhu, J.D. McCarter, L.P. Volak, B.E. Houk, M.
G. Fakih, B.H. O’Neil, T.J. Price, G.S. Falchook, J. Desai, J. Kuo, R. Govindan, D.
S. Hong, W. Ouyang, H. Henary, T. Arvedson, V.J. Cee, J.R. Lipford, The clinical
KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature 575 (7781)
(2019) 217–223.
[24] A. Drilon, G.R. Oxnard, D.S.W. Tan, H.H.F. Loong, M. Johnson, J. Gainor, C.
E. McCoach, O. Gautschi, B. Besse, B.C. Cho, N. Peled, J. Weiss, Y.J. Kim, Y. Ohe,
M. Nishio, K. Park, J. Patel, T. Seto, T. Sakamoto, E. Rosen, M.H. Shah, F. Barlesi, P.
A. Cassier, L. Bazhenova, F. De Braud, E. Garralda, V. Velcheti, M. Satouchi,
K. Ohashi, N.A. Pennell, K.L. Reckamp, G.K. Dy, J. Wolf, B. Solomon, G. Falchook,
K. Ebata, M. Nguyen, B. Nair, E.Y. Zhu, L. Yang, X. Huang, E. Olek, S.
M. Rothenberg, K. Goto, V. Subbiah, Efficacy of selpercatinib in RET fusionpositive non-small-cell lung cancer, N. Engl. J. Med. 383 (9) (2020) 813–824.
[25] J.C. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong, K.
H. Lee, A. Dechaphunkul, F. Imamura, N. Nogami, T. Kurata, I. Okamoto, C. Zhou,
B.C. Cho, Y. Cheng, E.K. Cho, P.J. Voon, D. Planchard, W.C. Su, J.E. Gray, S.M. Lee,
R. Hodge, M. Marotti, Y. Rukazenkov, S.S. Ramalingam, F. Investigators,
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer,
N. Engl. J. Med. 378 (2) (2018) 113–125.
[26] S. Peters, D.R. Camidge, A.T. Shaw, S. Gadgeel, J.S. Ahn, D.W. Kim, S.I. Ou,
M. Perol, R. Dziadziuszko, R. Rosell, A. Zeaiter, E. Mitry, S. Golding, B. Balas,
J. Noe, P.N. Morcos, T. Mok, A.T. Investigators, Alectinib versus crizotinib in
untreated ALK-positive non-small-cell lung cancer, N. Engl. J. Med. 377 (9) (2017)
829–838.
[27] A.T. Shaw, S.H. Ou, Y.J. Bang, D.R. Camidge, B.J. Solomon, R. Salgia, G.J. Riely,
M. Varella-Garcia, G.I. Shapiro, D.B. Costa, R.C. Doebele, L.P. Le, Z. Zheng, W. Tan,
P. Stephenson, S.M. Shreeve, L.M. Tye, J.G. Christensen, K.D. Wilner, J.W. Clark, A.
J. Iafrate, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N. Engl. J.
Med. 371 (21) (2014) 1963–1971.
[1] F. Griesinger, W. Eberhardt, A. Nusch, M. Reiser, M.O. Zahn, C. Maintz,
C. Bernhardt, C. Losem, A. Stenzinger, L.C. Heukamp, R. Buttner, N. Marschner,
M. Janicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert,
M. Heilmann, P. Sadjadian, W. Gleiber, C. Grah, C.F. Waller, M. Reck, A. Rittmeyer,
P. Christopoulos, M. Sebastian, M. Thomas, C.R. Group, Biomarker testing in nonsmall cell lung cancer in routine care: Analysis of the first 3,717 patients in the
German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315),
Lung Cancer 152 (2021) 174–184.
[2] F. Barlesi, J. Mazieres, J.-P. Merlio, D. Debieuvre, J. Mosser, H. Lena, L.H. Ouafik,
B. Besse, I. Rouquette, V. Westeel, F. Escande, I. Monnet, A. Lemoine, R. Veillon,
H. Blons, C. Audigier-Valette, P.-P. Bringuier, R. Lamy, M. Beau-Faller, J.-L. Pujol,
J.-C. Sabourin, F. Penault-Llorca, M.G. Denis, S. Lantuejoul, F. Morin, Q. Tran,
P. Missy, A. Langlais, B. Milleron, J. Cadranel, J.-C. Soria, G. Zalcman, Routine
molecular profiling of patients with advanced non-small-cell lung cancer: results of
a 1-year nationwide programme of the French Cooperative Thoracic Intergroup
(IFCT), Lancet 387 (10026) (2016) 1415–1426.
[3] P.J. Roberts, T.E. Stinchcombe, C.J. Der, M.A. Socinski, Personalized medicine in
non-small-cell lung cancer: is KRAS a useful marker in selecting patients for
epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 28 (31) (2010)
4769–4777.
[4] A.H. Nassar, Distribution of KRASG12C somatic mutations across race, sex and
cancer type, N. Engl. J. Med. 384 (2021) 185–187.
[5] F. Skoulidis, B.T. Li, G.K. Dy, T.J. Price, G.S. Falchook, J. Wolf, A. Italiano,
M. Schuler, H. Borghaei, F. Barlesi, T. Kato, A. Curioni-Fontecedro, A. Sacher,
A. Spira, S.S. Ramalingam, T. Takahashi, B. Besse, A. Anderson, A. Ang, Q. Tran,
O. Mather, H. Henary, G. Ngarmchamnanrith, G. Friberg, V. Velcheti, R. Govindan,
Sotorasib for lung cancers with KRAS p. G12C mutation, N. Engl. J. Med. 384 (25)
(2021) 2371–2381.
[6] D.S. Hong, M.G. Fakih, J.H. Strickler, J. Desai, G.A. Durm, G.I. Shapiro, G.
S. Falchook, T.J. Price, A. Sacher, C.S. Denlinger, Y.J. Bang, G.K. Dy, J.C. Krauss,
Y. Kuboki, J.C. Kuo, A.L. Coveler, K. Park, T.W. Kim, F. Barlesi, P.N. Munster, S.
S. Ramalingam, T.F. Burns, F. Meric-Bernstam, H. Henary, J. Ngang,
G. Ngarmchamnanrith, J. Kim, B.E. Houk, J. Canon, J.R. Lipford, G. Friberg,
P. Lito, R. Govindan, B.T. Li, KRAS(G12C) inhibition with sotorasib in advanced
solid tumors, N. Engl. J. Med. 383 (13) (2020) 1207–1217.
[7] J. Hallin, L.D. Engstrom, L. Hargis, A. Calinisan, R. Aranda, D.M. Briere,
N. Sudhakar, V. Bowcut, B.R. Baer, J.A. Ballard, M.R. Burkard, J.B. Fell, J.
P. Fischer, G.P. Vigers, Y. Xue, S. Gatto, J. Fernandez-Banet, A. Pavlicek,
K. Velastagui, R.C. Chao, J. Barton, M. Pierobon, E. Baldelli, E.F. Patricoin 3rd, D.
P. Cassidy, M.A. Marx, M.L. Rybkin II, S.I. Johnson, P. Ou, K.P. Lito, P.
A. Papadopoulos, P. Janne, J.G.C. Olson, The KRAS(G12C) inhibitor MRTX849
provides insight toward therapeutic susceptibility of KRAS-mutant cancers in
mouse models and patients, Cancer Discov. 10 (1) (2020) 54–71.
[8] Y. Jia, T. Jiang, X. Li, C. Zhao, L. Zhang, S. Zhao, X. Liu, M. Qiao, J. Luo, J. Shi,
H. Yang, Y. Wang, L. Xi, S. Zhang, G. Gao, C. Su, S. Ren, C. Zhou, Characterization
of distinct types of KRAS mutation and its impact on first-line platinum-based
chemotherapy in Chinese patients with advanced non-small cell lung cancer,
Oncol. Lett. 14 (6) (2017) 6525–6532.
[9] A.C. Tan, G.G.Y. Lai, G.S. Tan, S.Y. Poon, B. Doble, T.H. Lim, Z.W. Aung,
A. Takano, W.L. Tan, M.K. Ang, B.S. Tan, A. Devanand, C.W. Too, A. Gogna, B.
H. Ong, T.P.T. Koh, R. Kanesvaran, Q.S. Ng, A. Jain, T. Rajasekaran, A.S.T. Lim, W.
T. Lim, C.K. Toh, E.H. Tan, T.K.H. Lim, D.S.W. Tan, Utility of incorporating nextgeneration sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC)
population: incremental yield of actionable alterations and cost-effectiveness
analysis, Lung Cancer 139 (2020) 207–215.
[10] S. Matsumoto, T. Ikeda, Y. Zenke, T. Kato, S. Sugawara, K. Nishino, I. Nakachi,
H. Daga, N. Furuya, M. Morise, J. Sakakibara-Konishi, K. Yoh, K. Goto, Prospective
concordance study of a multi-gene PCR assay and NGS for the detection of
targetable gene alterations in lung cancer, J. Thoracic Oncol. 16 (3_Suppl) (2021)
S690.
[11] K.C. Arbour, H. Rizvi, A.J. Plodkowski, M.D. Hellmann, A. Knezevic, G. Heller, H.
A. Yu, M. Ladanyi, M.G. Kris, M.E. Arcila, C.M. Rudin, P. Lito, G.J. Riely, Treatment
outcomes and clinical characteristics of patients with KRAS-G12C-mutant nonsmall cell lung cancer, Clin. Cancer Res. 27 (2021) 2209–2215.
[12] A. Galan-Cobo, P. Sitthideatphaiboon, X. Qu, A. Poteete, M.A. Pisegna, P. Tong, P.
H. Chen, L.K. Boroughs, M.L.M. Rodriguez, W. Zhang, F. Parlati, J. Wang,
V. Gandhi, F. Skoulidis, R.J. DeBerardinis, J.D. Minna, J.V. Heymach, LKB1 and
KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with
enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma, Cancer
Res. 79 (13) (2019) 3251–3267.
[13] J.A. Hellyer, S.K. Padda, M. Diehn, H.A. Wakelee, Clinical implications of KEAP1NFE2L2 mutations in NSCLC, J. Thorac. Oncol. (2020).
[14] K.C. Arbour, E. Jordan, H.R. Kim, J. Dienstag, H.A. Yu, F. Sanchez-Vega, P. Lito,
M. Berger, D.B. Solit, M. Hellmann, M.G. Kris, C.M. Rudin, A. Ni, M. Arcila,
M. Ladanyi, G.J. Riely, Effects of co-occurring genomic alterations on outcomes in
patients with KRAS-mutant non-small cell lung cancer, Clin. Cancer Res. 24 (2)
(2018) 334–340.
111
Downloaded for Anonymous User (n/a) at Chutoen General Medical Center from ClinicalKey.jp by Elsevier on January 28,
2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.
...